FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Ontology highlight
ABSTRACT: In this Phase II study the investigators plan to determine the overall response rate (ORR) of the combination of FOLFOXIRI plus panitumumab as first-line treatment of patients with liver-only metastatic KRAS wild-type colorectal cancer.
DISEASE(S): Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2096992 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA